The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Akito NozakiMasanori AtsukawaChisa KondoHidenori ToyodaMakoto ChumaMakoto NakamutaHaruki UojimaKoichi TakaguchiHiroki IkedaTsunamasa WatanabeShintaro OgawaNorio ItokawaTaeang AraiAtsushi HiraokaToru AsanoShinichi FujiokaTadashi IkegamiToshihide ShimaChikara OgawaTakehiro AkahaneNoritomo ShimadaShinya FukunishiHiroshi AbeAkihito TsubotaTakuya GendaHironao OkuboShigeru MikamiAsahiro MorishitaAkio MoriyaJoji TaniYoshihiko TachiNaoki HottaToru IshikawaTakeshi OkanoueYasuhito TanakaTakashi KumadaKatsuhiko IwakiriShin Maedanull nullPublished in: Hepatology international (2020)
G/P regimen is highly effective and safe to treat CHC patients even with refractory factors such as CKD and advanced liver fibrosis. However, patients with past experience of IFN-free DAA treatment and genotype 3, CKD stage 4 or 5, and advanced liver fibrosis should be more closely observed.